FDA Approves Agios sNDA for Tibsovo as Monotherapy for Newly Diagnosed IDH1 Mutant AML Patients Not Eligible for Intensive Chemotherapy

FDA Approves Agios’ sNDA for Tibsovo as Monotherapy for Newly Diagnosed IDH1 Mutant AML Patients Not Eligible for Intensive Chemotherapy

15:29 EDT 2 May 2019 | Speciality Pharma Journal

CAMBRIDGE, Mass., May 02, 2019 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to update the U.S. Prescribing Information for TIBSOVO®, an isocitrate dehydrogenase-1 (IDH1) …

More From BioPortfolio on "FDA Approves Agios’ sNDA for Tibsovo as Monotherapy for Newly Diagnosed IDH1 Mutant AML Patients Not Eligible for Intensive Chemotherapy"